ReviewGeneral thoracic and cardiovascular surgery2016
Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.
Review in General thoracic and cardiovascular surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02938195 (Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta analysis of the second course of radiotherapy for recurrent esophageal cancer1.Journal of X-ray science and technology · 2024Pooled it
- Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis.Chinese medical journal · 2016Pooled it
- The role of SEC14L4 in esophageal squamous cell cancer: insights into clinical relevance and molecular pathways.Translational cancer research · 2024Article
- Timing After Neoadjuvant Therapy Predicts Mortality in Patients Undergoing Esophagectomy: a Propensity Score-Matched Analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Article
- Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study.Journal of thoracic disease · 2023Article
- lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer.Disease markers · 2023Article
- Article
- Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters.Journal of gastrointestinal cancer · 2019Article
- Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERASWorld journal of surgery · 2019Review
- Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma.General thoracic and cardiovascular surgery · 2018Article
- miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidisciplinary therapies have been developed to prolong the survival of patients with resectable esophageal cancer. Worldwide, neoadjuvant therapy has become the standard treatment for locally advanced resectable esophageal cancer. In this article, we briefly review the clinical trials and meta-analyses of neoadjuvant therapy for advanced esophageal cancer. In Europe and the USA, neoadjuvant chemoradiotherapy is regarded as the standard treatment, while neoadjuvant chemotherapy has become the standard treatment in Japan based on the results of clinical trials. Changes in treatment, according to the period and the results of up-to-date studies, are discussed. As neoadjuvant therapy is administered with the assumption that surgery will be performed, it is important for surgeons to be familiar with its impact on surgical management. We also review the impact of neoadjuvant therapy on surgical management. Issues such as the timing of surgery after neoadjuvant therapy, the extent of lymph node dissection, and the operative approach in relation to the esophagus are matters to be elucidated in the future.
Indexed as
Identifiers
27165288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.